Wall Street brokerages expect that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will post earnings per share (EPS) of ($1.62) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Agios Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.69) and the highest is ($1.53). Agios Pharmaceuticals reported earnings per share of ($1.78) during the same quarter last year, which would suggest a positive year-over-year growth rate of 9%. The company is expected to report its next quarterly earnings report on Tuesday, August 14th.
On average, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.41) per share for the current financial year, with EPS estimates ranging from ($6.73) to ($5.95). For the next year, analysts expect that the firm will post earnings of ($6.06) per share, with EPS estimates ranging from ($6.30) to ($5.77). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.03). Agios Pharmaceuticals had a negative return on equity of 61.70% and a negative net margin of 822.32%. The company had revenue of $8.80 million for the quarter, compared to analyst estimates of $11.93 million. During the same quarter in the prior year, the company earned ($1.56) earnings per share. The business’s revenue was down 16.2% compared to the same quarter last year.
AGIO has been the subject of several recent analyst reports. Piper Jaffray Companies reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 4th. SunTrust Banks set a $115.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 7th. Citigroup initiated coverage on Agios Pharmaceuticals in a research note on Wednesday, May 23rd. They set a “buy” rating and a $117.00 price objective for the company. Credit Suisse Group set a $95.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 7th. Finally, Cann reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 17th. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $95.55.
Agios Pharmaceuticals stock traded up $1.28 during mid-day trading on Friday, hitting $84.94. 331,060 shares of the company were exchanged, compared to its average volume of 323,130. Agios Pharmaceuticals has a 1-year low of $51.62 and a 1-year high of $99.82. The firm has a market capitalization of $4.82 billion, a P/E ratio of -12.58 and a beta of 2.01.
In other news, insider Christopher Bowden sold 2,000 shares of the stock in a transaction on Thursday, April 12th. The stock was sold at an average price of $85.10, for a total transaction of $170,200.00. Following the sale, the insider now owns 2,881 shares in the company, valued at $245,173.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Steven L. Hoerter sold 2,050 shares of the stock in a transaction on Monday, April 23rd. The stock was sold at an average price of $85.95, for a total value of $176,197.50. Following the sale, the insider now owns 2,050 shares in the company, valued at approximately $176,197.50. The disclosure for this sale can be found here. Insiders have sold 159,277 shares of company stock worth $14,357,650 in the last 90 days. Company insiders own 3.02% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Xact Kapitalforvaltning AB bought a new position in Agios Pharmaceuticals in the fourth quarter valued at about $259,000. S&CO Inc. bought a new position in Agios Pharmaceuticals in the first quarter valued at about $278,000. M&T Bank Corp bought a new position in Agios Pharmaceuticals in the first quarter valued at about $293,000. HBK Investments L P bought a new position in Agios Pharmaceuticals in the fourth quarter valued at about $306,000. Finally, Aperio Group LLC bought a new position in Agios Pharmaceuticals in the first quarter valued at about $311,000. Institutional investors own 94.51% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.